IMVT - Latest News
Immunovant, Inc. (IMVT), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $7.07B. Beta to the broader market is 0.84.
The article list below shows the most recent IMVT headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent IMVT Headlines
Does Immunovant (IMVT) Have the Potential to Rally 30.52% as Wall Street Analysts Expect?
zacks.com - Nov 11, 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 30. 5% in Immunovant (IMVT).
Don't Fight The Momentum: Roivant Has Big Expectations, But Real Pipeline Momentum
seekingalpha.com - Nov 11, 2026
Roivant Sciences Ltd. remains a Buy as its diversified "-vant" model delivers multiple blockbuster pipeline opportunities and robust cash reserves.
Immunovant (IMVT) Upgraded to Buy: Here's What You Should Know
zacks.com - Nov 11, 2026
Immunovant (IMVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive th
Immunovant, Inc. (IMVT) Q2 2027 Earnings Call Transcript
seekingalpha.com - Nov 9, 2026
Immunovant, Inc. ( IMVT ) Q2 2027 Earnings Call November 9, 2026 8:00 AM EST Company Participants Conference Call Participants Stephanie Lee Griffin
Immunovant Meets Primary Endpoint In Difficult-To-Treat Rheumatoid Arthritis Study
benzinga.com - Nov 9, 2026
Immunovant (NASDAQ:IMVT) announced on Monday positive efficacy results from a clinical trial evaluating IMVT-1402 in patients with difficult-to-treat
How News Affects IMVT Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track IMVT's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked IMVT news questions
- What is the latest IMVT news headline?
- The most recent IMVT headline (Nov 11, 2026) is "Does Immunovant (IMVT) Have the Potential to Rally 30.52% as Wall Street Analysts Expect?". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the IMVT news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What IMVT news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual IMVT options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.